Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study - Wikidata - awgldk - TriplyDB

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

http://www.wikidata.org/entity/Q28257337

about

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia Monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia Ofatumumab: a novel monoclonal anti-CD20 antibody The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia Ofatumumab Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data New developments in the management of chronic lymphocytic leukemia: role of ofatumumab Ofatumumab Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia Translating basic mechanisms of IgG effector activity into next generation cancer therapies Developing strategies in the immunotherapy of leukemias Monoclonal antibodies for the treatment of cancer Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Ocrelizumab: a step forward in the evolution of B-cell therapy Diffuse large B-cell lymphoma: current strategies and future directions Novel CD20 monoclonal antibodies for lymphoma therapy Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.Antibody Therapies in Cancer.Alemtuzumab for B-cell chronic lymphocytic leukemia.Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.Ofatumumab combined with chlorambucil for previously untreated chronic lymphocytic leukemia: a phase I/II, open-label study in Japan.Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis.New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia.A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805.Ofatumumab, a human anti-CD20 monoclonal antibody.Monoclonal antibodies: versatile platforms for cancer immunotherapy.Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance.

P2860

Q24203027-04F3290B-7452-454A-ADBE-AAB475F78E3C Q24241519-CCE356D2-3FFA-4B0C-9582-C27C0E3BD54F Q24604065-6E288478-CA6D-4B62-AACD-73F907064981 Q24605471-D4BC6701-A69F-4A25-A3B9-11C82FE049C8 Q24617708-3AE5CD12-C730-4F51-A5F3-6613AC89D899 Q24651912-ECFFC9F0-B479-4720-9ABC-34247DD1A77F Q26738934-7C29ED08-3251-42E6-8791-4AC249BEC003 Q26768396-25E84449-31BE-4E16-A6CB-9F0463E314A9 Q26773260-4BAA6992-3118-42C1-9215-F73CD6AC1FFC Q26782270-38D163B5-CB44-4435-BAF7-1D76AAB9581B Q26783600-46EA9A97-DA6F-48A3-8BFA-572D607996CE Q26991899-820EC410-030B-4249-AC95-50498E57BF01 Q26996310-1D55B181-5201-494E-B30C-EEBB70E63265 Q27025966-635CDB57-FF9D-4AE4-A70B-8EB12D16BA20 Q28075606-3F464BBA-8037-42C6-A6DE-4693C5DED4C9 Q28245986-A1A53EF7-7422-4D8A-B167-5EF69D1DCC4B Q28269136-994F1027-1FCB-47CF-BD0F-0DFB7267DED4 Q28390112-4A52501F-611D-4708-A356-051A50D435F5 Q30405847-A8E58978-9160-46B4-AEA1-6DD428328D55 Q30423909-65F1E6B3-AC7A-4463-A634-366C8C1225D5 Q30439017-5B1546D7-EEB2-47F3-AC3D-96AE44EE723A Q31033615-5921FF39-417C-48FB-AB17-2B5A79E19FED Q31104000-8FDDBEC9-6415-4718-8415-1341974F36F5 Q33380135-0A31E61A-4E1F-4103-92BE-C43D974A1CF8 Q33385389-21080F4D-878E-478D-A739-23BF69807F24 Q33394947-62B1D983-AFD5-4C1A-8CC0-70E6AD537723 Q33419843-8F6B1B03-4279-42D6-8E48-ABEE93609E3E Q33441123-D6BEAB72-BA7B-40B0-B619-2CA494849504 Q33442438-50237916-E7F9-4851-A7A0-54AB2D96EFE7 Q33564645-07E9EE01-4D94-4A9A-A0AB-75383ADB4821 Q33566063-95D719D2-2739-4003-9391-6811BEBFFAE0 Q33626106-7ED84C00-AC39-487F-B770-D351F3C283EF Q33733542-214E995B-0E21-4B2A-B293-702F21EA3243 Q33880538-CD71A847-0ECA-442C-B68A-D396D5353DB8 Q33900573-80FF959E-00A7-4946-A482-4D4626D287A3 Q34095311-D63B15CE-EC72-4690-9877-4397C22A675F Q34111693-8621D4C0-715E-4C1F-9FC8-D960F059B6AB Q34147379-70CFBF27-9548-42CC-BFA5-70BAE190CFF2 Q34202277-2885EA10-90BF-4277-9EA3-9E4DB9ED623D Q34255124-20AF716E-E0CF-4E58-8182-B8FB0ABCAC0B

P2860

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

http://www.wikidata.org/entity/Q28257337

description

2008 nî lūn-bûn

@nan

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Safety and efficacy of ofatumu ...... ic leukemia: a phase 1-2 study

@ast

Safety and efficacy of ofatumu ...... ic leukemia: a phase 1-2 study

@en

Safety and efficacy of ofatumu ...... ic leukemia: a phase 1-2 study

@nl

type

label

Safety and efficacy of ofatumu ...... ic leukemia: a phase 1-2 study

@ast

Safety and efficacy of ofatumu ...... ic leukemia: a phase 1-2 study

@en

Safety and efficacy of ofatumu ...... ic leukemia: a phase 1-2 study

@nl

prefLabel

Safety and efficacy of ofatumu ...... ic leukemia: a phase 1-2 study

@ast

Safety and efficacy of ofatumu ...... ic leukemia: a phase 1-2 study

@en

Safety and efficacy of ofatumu ...... ic leukemia: a phase 1-2 study

@nl

P1433

Q28257337-891E8AA2-4581-4392-BC1E-68A79BF32456

P1476

Q28257337-3081EE12-7BF1-42BA-A791-A775794CE1C9

P2093

Q28257337-1405FF49-BFB3-4255-9E43-DF7BFBFF2AB1

Q28257337-1EC4BAB6-E21F-4356-84D2-4FADA810E87D

Q28257337-3F548C4B-8F2E-407E-9EDD-10F9A4B5FA38

Q28257337-4CBA1739-9907-405D-80E8-FFEA29DACD8B

Q28257337-594499D9-A3C8-4999-B0AA-A37EA8D900F6

Q28257337-6F06F8D2-C9AB-44A3-83D1-BC1AEC126A88

Q28257337-8085891E-3991-4152-95E3-F743AF1D51E5

Q28257337-8A7E3AF4-14DA-4669-8380-BBFBA264DA16

Q28257337-8DDCD81D-A8CB-47F9-A687-4B16F3D7F09D

Q28257337-B277FA89-9A79-4D1E-B9A7-9D17C9A5AFC9

P304

Q28257337-D73D06C0-2192-4A37-AD12-73E7121B04F3

P31

Q28257337-AD277994-977E-4F46-8E18-E557BF7B118D

P3181

Q28257337-D8D0E6DE-5147-46C7-8C8A-B2FE1B235EF9

P356

Q28257337-EBC463AC-2B02-424A-B293-F8D5B28A79D2

P407

Q28257337-98A5DCAF-C03D-4C32-952E-F7E938EFB2E7

P433

Q28257337-E20BCCD7-1E14-4EE2-93A8-ABB9B560E199

P478

Q28257337-A6D403A0-BFCE-4D2B-8F73-A192C3694C0B

P577

Q28257337-67C73BDF-8978-4393-9401-DF8BB6C0BA51

P698

Q28257337-B80A3947-90F6-4731-BDFD-862BE220129E

P921

Q28257337-3D028D4C-9641-4387-A68B-975B87E2AFD6

Q28257337-8DD97786-9E03-463E-8953-3584BEE86DC0

Q28257337-95382B1A-DC37-4701-A269-869B44999DF3

Q28257337-C84E6F8F-1D65-4572-B620-E66755B3F2D3

P3181

P356

BLOOD-2007-09-111781

P1433

P1476

Safety and efficacy of ofatumu ...... ic leukemia: a phase 1-2 study

@en

P2093

Andrzej Hellmann

http://www.w3.org/2001/XMLSchema#string

Bertrand Coiffier

http://www.w3.org/2001/XMLSchema#string

Henrik Fredriksen

http://www.w3.org/2001/XMLSchema#string

James Wooldridge

http://www.w3.org/2001/XMLSchema#string

Jan Walewski

http://www.w3.org/2001/XMLSchema#string

Janusz Kloczko

http://www.w3.org/2001/XMLSchema#string

Jerzy Holowiecki

http://www.w3.org/2001/XMLSchema#string

Jørgen Petersen

http://www.w3.org/2001/XMLSchema#string

Lars Møller Pedersen

http://www.w3.org/2001/XMLSchema#string

Marinus H J van Oers

http://www.w3.org/2001/XMLSchema#string

P304

1094-100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4885867

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2007-09-111781

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18003886

http://www.w3.org/2001/XMLSchema#string

P921